If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
29/08/2025 [06:52:00]
Results 50 to 75 of 174
Absstract of: MX2025000539A
The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.
Absstract of: WO2025172762A1
This invention introduces a method of development for a nanodrug that releases HOCl at tumor sites for treating lung cancer. The process involves creating alginate chitosan nanoparticles, measuring folate conjugation to chitosan, studying the properties of the nanoparticles, assessing HOCl release and cytotoxicity, and evaluating the impact on cancer cells by analyzing protein expression. Additionally, the penetration and effects of the nanoparticles are studied in a mouse model of lung cancer to understand their behavior in vivo. Overall, this patent aims to develop a targeted and effective treatment for lung cancer with minimal side effects on healthy tissues.
Absstract of: WO2025171440A1
Lipid-based nanoparticles containing lipids, phenolic compounds, and, optionally, metal ions are provided. In certain forms, the nanoparticles adopt non-lamellar, lyotropic, liquid crystalline structures. Bioactive lipid-based nanoparticles containing one or more active agents are also provided as are methods of treating diseases or conditions with said bioactive lipid-based nanoparticles and formulations thereof.
Absstract of: WO2025172945A1
The invention relates to the field of medicine, and more particularly to bioengineering, genetic engineering, gene editing, molecular medicine, nanotechnology, biotechnology, nanoengineering and protein engineering. The invention can be used for packaging a Cas protein and a guide RNA, separately or together in the form of ribonucleoprotein complexes, and for packaging a Cas protein and a guide RNA of any class, type, form, origin and modification.
Absstract of: WO2025175107A1
Disclosed herein are compositions and methods for modifying B cells. Particles such as hydrophobic microparticles or nanoparticles are described for use in delivering agents to B cells, generating regulatory B cells and inducing IL-10 production by B cells. Particles, or B cells bound to the same, are also provided for use in methods for treating an inflammatory or autoimmune disease or condition, inducing immune tolerance, and sustained delivery of an agent to a subject.
Absstract of: US2025263678A1
The disclosure relates to compositions and methods for the treatment of fibrotic diseases and disorders and/or liver diseases and disorders, with one or more synthetic messenger ribonucleic acids (mRNAs) encoding telomerase reverse transcriptase (TERT).
Absstract of: US2025263675A1
Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a poly peptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.
Absstract of: US2025262894A1
The present invention is directed to additive manufacturing compositions and methods for producing additive manufacturing composite blends with oxidized discrete carbon nanotubes with dispersion agents bonded to at least one sidewall of the oxidized discrete carbon nanotubes. Such compositions are especially useful when radiation cured, sintered or melt fused.
Absstract of: US2025262320A1
This disclosure relates to mRNA therapy for the treatment of Crigler-Najjar Syndrome Type 1 (CN-1). mRNAs for use in the invention, when administered in vivo, encode uridine diphosphate glycosyltransferase 1 family, polypeptide A1 (UGT1A1). mRNA therapies of the disclosure increase and/or restore deficient levels of UGT1A1 expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of bilirubin associated with deficient UGT1A1 activity in subjects.
Absstract of: US2025262324A1
Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Absstract of: US2025262231A1
We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.
Absstract of: US2025262311A1
The present disclosure provides, in some aspects, nucleic acid nanostructures covalently linked to oligolysine-PEG copolymers.
Absstract of: WO2025174825A2
This disclosure provides, for instance, novel lipids suitable for use in lipid nanoparticles, for therapeutic delivery of nucleic acids. Also provided are methods of making and using the lipids.
Absstract of: US2025262166A1
The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nanoparticles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, processes for the preparation of such pharmaceutical dosage forms, and uses of the pharmaceutical dosage forms for medical purposes.
Absstract of: US2025262156A1
Hybrid nanoparticles having a defined size in a range between about 50 nm to about 1000 nm prepared by a kinetic assembly process are disclosed. The hybrid nanoparticles comprise a biodegradable polycation and a PEGylated lipid and include a nucleic acid including, but not limited to, plasmid DNA, messenger RNA (mRNA), small interfering RNA (siRNA), and the like. The assembled hybrid nanoparticles can be used for gene delivery therapy in vivo through various delivery routes and ex vivo and in vitro to transfect cells of interest. The disclosed hybrid nanoparticles with certain sizes within a sub-micron range exhibited significantly improved transfection efficiency compared to nanoparticles without size control.
Absstract of: US2025262158A1
Method for producing high yield nano-in-micro (NIM) encapsulated bioactive siRNA dry powder comprising the steps of: —providing an aqueous suspension comprising polyplexes, in particular polyelectrolyte complexes, formed from at least a polyamine, and/or polyamide and/or polyester and siRNA, wherein the polyplexes are provided with and/or encapsulated into water soluble excipients, in particular highly purified water and/or sugar alcohol and/or sugar; —spray drying the aqueous suspension using a spray In drying apparatus, preferably a Büchi B-290, by feeding the aqueous suspension to a spray drying atomizing nozzle and subjecting the atomized droplets to a heated gas stream of a carrier gas, preferably dried and cleaned air, in particular through a multicomponent atomizing nozzle for the suspension and an atomizing gas; —collecting a spray dried powder in an accumulation means of the spray drying apparatus characterized in that the temperature in the vicinity of an outlet opening of the spray drying apparatus, in particular an outlet opening connecting a spray drying chamber with the accumulation means, during feeding of the aqueous suspension to the nozzle is controlled by temperature controlling means to be limited to an upper threshold temperature which is equal to or below a melting temperature of the respective naked siRNA.
Absstract of: US2025262146A1
This invention relates to a nanogel platform technology that can increase the water solubility of hydrophobic compounds, particularly hydrophobic compounds having one or more double bonds, by more than about 400 fold. Methods according to embodiments of the invention involve copolymerizing the hydrophobic compound with N-isopropylacrylamide monomer and dextran-lactate-2-hydroxyethyl-methacrylate macromer via UV emulsion polymerization in aqueous solution. The resulting nanosystem has the additional advantage of being able to sustain the release of the drug candidate for a long period of time, thus increasing the half-life, long-term bioavailability and therapeutic effects of these hydrophobic compounds.
Absstract of: US2025262178A1
A nanoemulsion for topical drug delivery, comprising diclofenac alkali metal salt, diclofenac free acid, a solvent of the glycol, or glycol ether or glycol ether ester family, a nonionic surfactant with a hydrophilic lipophilic balance (HLB) value of about 14-16, caprylic capric triglyceride, and water. The nanoemulsion is useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.
Absstract of: WO2025174765A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Absstract of: WO2025174858A1
The present disclosure provides cationic lipid compounds having the following Structure (I): where G1, G2, R1, R2, R3a, R3b, R3c, R3d, R4a, R4b, R4c, R4d, L1, L2, and L3 are as defined herein. The present disclosure also discloses pharmaceutically acceptable salts or stereoisomers thereof. Also provided by the present disclosure are uses of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: WO2025172861A2
This invention relates to compositions including acid addition salt formulations including a compound of formula (I). Also disclosed are methods of their use and preparation.
Absstract of: WO2025172284A1
The present disclosure includes ionizable lipids suitable for lipid nanoparticle compositions and pharmaceutical formulations thereof. The lipids have general formula (I).
Absstract of: AU2025213607A1
A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. ug t a r g e t a b l e n a n o c o n s t r u c t c a p a b l e o f s i m u l t a n e o u s l y s e r v i n g a s a t h e r a p e u t i c u g p l a t f o r m f o r p h o t o d y n a m i c t h e r a p y a s w e l l a s a n m o l e c u l a r i m a g i n g a g e n t , f r e e o f h e a v y m e t a l a t o m s - c y s t a r g e t i n g a g e n t n a n o c o n s t r u c t s , i n c l u d i n g - e s l a b e l - f r e e n a n o c o n s t r u c t t h a t c a n b e d i r e c t l y a n d s e l e c t i v e l y i m a g e d b y , u s i n g s t a n d a r d s p i n - e c h o i m a g i n g s e q u e n c e s w i
Absstract of: AU2024219072A1
The present invention provides novel antigen-capturing nano-particles (ACNPs) and pharmaceutical formulations containing such ACNPs. Also provided herein are methods for preparing the ACNP formulations, and methods for the treatment of a disease (such as cancer) in a subject with the ACPNs or a pharmaceutical formulation containing the ACPNs.
Nº publicación: AU2024208147A1 21/08/2025
Applicant:
SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD
SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD
Absstract of: AU2024208147A1
An amino lipid compound, and a preparation method therefor and the use thereof. The present invention further relates to a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.
BOPI
Electronic site
